Interestingly, DNMT inhibitors sensitized a pre-clinical melanoma model to CTLA-4 immunotherapy [107] by de-repressing endogenous retroviruses (ERVs) and activating an IFN response. This evidence concerns the gene CTLA4 and melanoma.